Search results
Results from the WOW.Com Content Network
Dihydropyridine (DHP) calcium channel blockers are derived from the molecule dihydropyridine and often used to reduce systemic vascular resistance and arterial pressure. Sometimes when they are used to treat angina , the vasodilation and hypotension can lead to reflex tachycardia , which can be detrimental for patients with ischemic symptoms ...
ATC code C08 Calcium channel blockers is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] Subgroup C08 is part of the anatomical group C Cardiovascular system ...
Calcium channel blockers (CCBs) preferentially block the L-type voltage-gated calcium channels to prevent the flow of calcium influx in the blood vessels and the heart, thereby reducing peripheral vascular resistance and cardiac output respectively. [10] Dihydropyridines (DHP): amlodipine, nifedipine, felodipine, nicardipine
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
Compared with certain other L-type calcium channel blockers (for example those of the phenylalkylamine class such as verapamil) that have significant action at the heart, the dihydropyridine calcium channel blockers lower blood pressure mainly by relaxing the smooth muscle of the blood vessel walls. [3]
Zalicus Presents Data on Novel, Oral, N- and T-Type Calcium Channel Blockers for the Treatment of Pain Preclinical Data on Z160 and Z944 Presented at the American Pain Society 2013 Annual Meeting ...
An L-type calcium channel with its subunits labeled along with some drugs known to inhibit the channel. The L-type calcium channel (also known as the dihydropyridine channel, or DHP channel) is part of the high-voltage activated family of voltage-dependent calcium channel. [2] "L" stands for long-lasting referring to the length of activation.
Class IV agents are slow non-dihydropyridine calcium channel blockers. They decrease conduction through the AV node , and shorten phase two (the plateau) of the cardiac action potential . They thus reduce the contractility of the heart, so may be inappropriate in heart failure.